These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 8410302)

  • 1. Internal dosimetry using data derived from autoradiographs.
    Humm JL; Macklis RM; Bump K; Cobb LM; Chin LM
    J Nucl Med; 1993 Oct; 34(10):1811-7. PubMed ID: 8410302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A model of cell inactivation by alpha-particle internal emitters.
    Humm JL; Chin LM
    Radiat Res; 1993 May; 134(2):143-50. PubMed ID: 8488249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonuniformity of tumor dose in radioimmunotherapy.
    Humm JL; Cobb LM
    J Nucl Med; 1990 Jan; 31(1):75-83. PubMed ID: 2295944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo.
    Bäck T; Andersson H; Divgi CR; Hultborn R; Jensen H; Lindegren S; Palm S; Jacobsson L
    J Nucl Med; 2005 Dec; 46(12):2061-7. PubMed ID: 16330571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicellular dosimetry for micrometastases: dependence of self-dose versus cross-dose to cell nuclei on type and energy of radiation and subcellular distribution of radionuclides.
    Goddu SM; Rao DV; Howell RW
    J Nucl Med; 1994 Mar; 35(3):521-30. PubMed ID: 8113908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Image analysis for the study of radionuclide distribution in tissue sections.
    Humm JL; Macklis RM; Yang Y; Bump K; Chin LM
    J Nucl Med; 1994 Jul; 35(7):1217-25. PubMed ID: 8014686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35.
    Elgqvist J; Andersson H; Bäck T; Hultborn R; Jensen H; Karlsson B; Lindegren S; Palm S; Warnhammar E; Jacobsson L
    J Nucl Med; 2005 Nov; 46(11):1907-15. PubMed ID: 16269606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
    Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with 211At-MX35 F(ab')2.
    Elgqvist J; Andersson H; Bernhardt P; Bäck T; Claesson I; Hultborn R; Jensen H; Johansson BR; Lindegren S; Olsson M; Palm S; Warnhammar E; Jacobsson L
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1228-37. PubMed ID: 17145538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myelotoxicity and RBE of 211At-conjugated monoclonal antibodies compared with 99mTc-conjugated monoclonal antibodies and 60Co irradiation in nude mice.
    Elgqvist J; Bernhardt P; Hultborn R; Jensen H; Karlsson B; Lindegren S; Warnhammar E; Jacobsson L
    J Nucl Med; 2005 Mar; 46(3):464-71. PubMed ID: 15750160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters.
    Behr TM; Sgouros G; Stabin MG; Béhé M; Angerstein C; Blumenthal RD; Apostolidis C; Molinet R; Sharkey RM; Koch L; Goldenberg DM; Becker W
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3031s-3043s. PubMed ID: 10541340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implementation and evaluation of patient-specific three-dimensional internal dosimetry.
    Kolbert KS; Sgouros G; Scott AM; Bronstein JE; Malane RA; Zhang J; Kalaigian H; McNamara S; Schwartz L; Larson SM
    J Nucl Med; 1997 Feb; 38(2):301-8. PubMed ID: 9025759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicellular dosimetry for beta-emitting radionuclides: autoradiography, thermoluminescent dosimetry and three-dimensional dose calculations.
    Yorke ED; Williams LE; Demidecki AJ; Heidorn DB; Roberson PL; Wessels BW
    Med Phys; 1993; 20(2 Pt 2):543-50. PubMed ID: 8492763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular dosimetry: absorbed fractions for monoenergetic electron and alpha particle sources and S-values for radionuclides uniformly distributed in different cell compartments.
    Goddu SM; Howell RW; Rao DV
    J Nucl Med; 1994 Feb; 35(2):303-16. PubMed ID: 8295004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microdosimetric analysis of alpha-particle-emitting targeted radiotherapeutics using histological images.
    Akabani G; Kennel SJ; Zalutsky MR
    J Nucl Med; 2003 May; 44(5):792-805. PubMed ID: 12732682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
    Postema EJ; Börjesson PK; Buijs WC; Roos JC; Marres HA; Boerman OC; de Bree R; Lang M; Munzert G; van Dongen GA; Oyen WJ
    J Nucl Med; 2003 Oct; 44(10):1690-9. PubMed ID: 14530488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microdosimetric analysis for high LET radiation.
    Lu XQ; Kiger WS
    Radiat Prot Dosimetry; 2006; 122(1-4):374-7. PubMed ID: 17276997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implications of nonuniform tumor doses for radioimmunotherapy.
    O'Donoghue JA
    J Nucl Med; 1999 Aug; 40(8):1337-41. PubMed ID: 10450686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments.
    Casey JL; Pedley RB; King DJ; Green AJ; Yarranton GT; Begent RH
    Br J Cancer; 1999 Nov; 81(6):972-80. PubMed ID: 10576653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.